

ANNEX II

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**
- D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

CEVA-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5
1107 Budapest
HUNGARY

Name and address of the manufacturer responsible for batch release

CEVA-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5
1107 Budapest
HUNGARY

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

C. STATEMENT OF THE MRLs

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

**D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION**

Specific pharmacovigilance requirement(s):

The MAH should provide an additional PSUR.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON BOX for 40 ml or 100 ml plastic bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

COXEVAC suspension for injection for cattle, goats and sheep

2. STATEMENT OF ACTIVE SUBSTANCES

Inactivated *Coxiella burnetii*, strain Nine Mile ≥ 72 QF Units/ml

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

40 ml
100 ml

5. TARGET SPECIES

Cattle, goats and sheep

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s): zero days.

9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP {month/year}
Once broached, use within 10 hours.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd
Explorer House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0HH
United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

Vm 15052/5000

17. MANUFACTURER'S BATCH NUMBER

LOT {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

100 ml plastic bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

COXEVAC suspension for injection for cattle, goats and sheep

2. STATEMENT OF ACTIVE SUBSTANCES

Inactivated *Coxiella burnetii*, strain Nine Mile ≥ 72 QF Units/ml

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

100 ml

5. TARGET SPECIES

Cattle , goat and sheep

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

SC
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s): zero days.

9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP {month/year}
Once broached, use within 10 hours.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd
Explorer House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0HH
United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

Vm 15052/5000

17. MANUFACTURER’S BATCH NUMBER

Batch {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

40 ml plastic bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

COXEVAC suspension for injection for cattle, goats and sheep

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Inactivated *Coxiella burnetii*, strain Nine Mile ≥ 72 QF Units/ml

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

40 ml

4. ROUTE(S) OF ADMINISTRATION

SC

5. WITHDRAWAL PERIOD(S)

Withdrawal period(s): zero days.

6. BATCH NUMBER

LOT {number}

7. EXPIRY DATE

EXP {month/year}
Once broached, use within 10 hours.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET:
COXEVAC suspension for injection for cattle and goats

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Ceva Animal Health Ltd
Explorer House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0HH
United Kingdom

Manufacturer responsible for batch release:

CEVA-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5
1107 Budapest
HUNGARY

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

COXEVAC suspension for injection for cattle, goats and sheep

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

Active substance:

Inactivated *Coxiella burnetii*, strain Nine Mile ≥ 72 QF Units*

*QF (Q fever) Unit: relative potency of phase I antigen measured by ELISA in comparison with a reference item.

Excipients:

Thiomersal $\leq 120 \mu\text{g}$.

Whitish, opalescent, homogeneous suspension.

4. INDICATION(S)

Cattle:

For the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in

comparison with animals receiving a placebo), and to reduce shedding of *Coxiella burnetii* in these animals via milk and vaginal mucus.

Onset of immunity: not established.

Duration of immunity: 280 days after completion of the primary vaccination course.

Goats:

For the active immunisation of goats to reduce abortion caused by *Coxiella burnetii* and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta.

Onset of immunity: not established.

Duration of immunity: one year after completion of the primary vaccination course.

Sheep:

For the active immunisation of sheep against *Coxiella burnetii* to reduce shedding of the organism via milk, vaginal mucus and faeces.

Onset of immunity: not established

Duration of immunity: 4 months

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

Cattle:

It was very common to see in laboratory trials a palpable reaction of maximum diameter of 9 to 10 cm at the injection site, which may last for 17 days. The reaction gradually reduces and disappears without need for treatment.

Systemic signs as lethargy, hyperthermia and/or anorexia have been observed rarely in post marketing safety experience.

Goats:

It was very common to see in laboratory trials a palpable reaction of 3 to 4 cm diameter at the injection site which may last for 14 days. The reaction reduces and disappears without need for treatment.

It was very common to observe in laboratory trials a slight increase of rectal temperature for 4 days post-vaccination.

Systemic signs as lethargy, malaise and/or anorexia have been observed uncommonly in post marketing safety experience.

Diarrhoea has been observed rarely in post marketing safety experience.

Sheep:

It was very common to see in laboratory trials moderate palpable reaction at the injection site which may last longer than 14 days. The reaction reduces and disappears without need for treatment.

Systemic signs as lethargy, hyperthermia and/or anorexia have been observed rarely in post marketing safety experience.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Cattle, goats and sheep

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

Shake well before use.

Administer the vaccine as follows:

Cattle: 4 ml in the neck region.

Goats: 2 ml in the neck region.

Sheep: 2ml in the neck region.

Cattle from 3 months of age:

Primary vaccination:

Two doses should be given subcutaneously with an interval of 3 weeks. Under normal conditions the timing of vaccination should be planned so that the primary course is completed by 3 weeks before artificial insemination or mating.

Re-vaccination:

Every 9 months, as described for primary vaccination, based on a duration of immunity of 280 days.

Goats from 3 months of age:

Primary vaccination:

Two doses should be given subcutaneously with an interval of 3 weeks. Under normal conditions the timing of vaccination should be planned so that the primary course is completed by 3 weeks before artificial insemination or mating.

Re-vaccination:

One dose should be given yearly.

Sheep from 4 months of age:

Primary vaccination:

Two doses should be given subcutaneously with an interval of 3 weeks. The vaccination should be done as late as possible but the primary course is needs to be completed by 3 weeks before artificial insemination or mating.

Re-vaccination:

Prior to each artificial insemination or mating, two doses, 3 weeks apart; the vaccination course should be done as late as possible but needs to be completed at least 3 weeks before the intended start of the reproduction phase.

9. ADVICE ON CORRECT ADMINISTRATION

Shake well before use.
Respect normal aseptic conditions.

10. WITHDRAWAL PERIOD(S)

Meat, milk and offal: Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2°C– 8°C).
Do not freeze.
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after {EXP}.
Shelf life after first opening the container: 10 hours.

12. SPECIAL WARNING(S)

Special warnings for each target species:

Vaccination of animals already infected at the time of vaccination will have no adverse effect.

No efficacy data are available concerning the use of the vaccine in male animals. However, in safety laboratory trials, the use of the vaccine in males proved to be safe. In the case that it is decided to vaccinate the whole herd, it is advisable to vaccinate the male animals at the same time.

The biological significance of the levels of reduction shown in shedding in cattle and goats is not known.

Special precautions for use in animals:

It is advisable to vaccinate all the animals in the herd at the same time. Under field conditions, vaccination with COXEVAC has commonly been followed by a decrease in milk production in goats. Since stress could contribute to this adverse reaction, appropriate precautions should be taken to reduce stress as much as possible during the administration of the product.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label, to the physician.

Pregnancy:

There are no benefits of the vaccine (as described in the indications for cattle), when used in infected and/or pregnant cows.

Cattle and goats:

The safety of the veterinary medicinal product has not been established during pregnancy.

The vaccine can be used during lactation.

Under field conditions, vaccination with COXEVAC has been followed by a decrease in milk production, commonly in goats and rarely in cattle. Since stress could contribute to this adverse reaction, appropriate precautions should be taken to reduce stress as much as possible during the administration of the product.

Sheep:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Overdose (symptoms, emergency procedures, antidotes):

Cattle:

With double dose, a palpable reaction of maximum diameter of 10 cm was observed at the injection site, lasting for 16 days. The reaction gradually reduced and disappeared without need for treatment.

Goats:

With double dose, a moderate palpable reaction of diameter of 4 to 5 cm was observed at the injection site, lasting for 4 days. The reaction reduced and disappeared without need for treatment.

Sheep:

With double dose, a moderate palpable reaction of diameter of less than 2 cm was observed at the injection site, lasting for 12 days. The reaction reduced and disappeared without need for treatment. Nasal shedding has also been observed after vaccination with double dose lasting one day.

Incompatibilities:

Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

15. OTHER INFORMATION

The vaccine contains phase I *Coxiella burnetii* as active ingredient inducing active immunity against Q fever in cattle and goats.

Pack sizes: 40 ml or 100 ml in a plastic LDPE bottle.

Not all pack sizes may be marketed.

The manufacture, import, possession, sale, supply and/or use of COXEVAC may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. Any person intending to manufacture, import, possess, sell, supply and use COXEVAC must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.

Gavin Hall

Approved: 22 December 2024